譽衡藥業(002437.SZ):參股公司譽衡生物擬引入戰投增資2億元
格隆匯4月6日丨譽衡藥業(002437.SZ)公佈,公司參股公司廣州譽衡生物科技有限公司(簡稱“譽衡生物”)基於其經營發展需要,擬引入新戰略投資者宜興環科園產發股權投資合夥企業(有限合夥)(簡稱“宜興環科園”),宜興環科園擬以人民幣1.72元/註冊資本的對價向譽衡生物增資人民幣2億元,公司放棄該次增資優先認購權,增資完成後,宜興環科園將佔譽衡生物16.59%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.